IP Library Granted Patent US 11,505,781
Granted Patent B2
US 11,505,781 · App. 16/467,911 · Granted Nov 22, 2022

Compositions and methods for maturation of oocytes in vitro

Inventor: Mark Brenton Nottle (Bibaringa, AU)
C12N5/0609C12N2501/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,505,781
App. No.
16/467,911
Granted
Nov 22, 2022
Kind
B2
Abstract

The present invention relates to culture media for oocytes and uses thereof. Specifically, media for culturing an oocyte in vitro are disclosed, wherein said media comprise granulocyte macrophage-colony stimulating factor (GM-CSF). The presence of GM-CSF in the media increases the maturation and/or developmental competence of the oocyte making it suitable for use in subsequent assisted reproductive technologies. Methods for increasing the maturation and/or developmental competence of an oocyte are also disclosed.

Claims (6)

1. A method of increasing maturation or increasing developmental competence of a mammalian oocyte in vitro, the method comprising culturing the oocyte in vitro in a mammalian oocyte maturation medium comprising species-specific granulocyte macrophage-colony stimulating factor (GM-CSF), wherein the level of maturation or developmental competence is greater than that of a mammalian oocyte of the same species when cultured in a medium which does not comprise GM-CSF, and wherein an embryo derived from the oocyte cultured in the oocyte maturation medium has improved development when compared to an embryo derived from an oocyte of the same species when cultured in a medium which does not comprise GM-CSF.

2. The method of claim 1 , wherein the improved development of the embryo is one or more of an increased on time blastocyst development, an increased blastocyst inner cell mass number, increased blastocyst rate, increased trophectoderm cell number, increased blastocyst total cell number, and increased viability.

3. The method of claim 1 , wherein the improved development of the embryo is due to decreased DNA damage in a blastocyst derived from the oocyte cultured in the medium.

4. The method of claim 1 , wherein the improved development of the embryo is one or more of increased implantation, pregnancy rate, and development to term, in a recipient following transfer of an embryo derived from the oocyte cultured in the medium to the recipient.

5. The method of claim 1 , wherein the mammalian oocyte is selected from the group consisting of a human oocyte, a bovine oocyte, a porcine oocyte, an equine oocyte, a canine oocyte, a feline oocyte, a murine oocyte, an ovine oocyte, and a non-human primate oocyte.

6. The method of claim 1 , wherein the amount of GM-CSF present in the medium is about 0.1 ng/ml to about 100 ng/ml.

Assignments (1)
NUNC PRO TUNC ASSIGNMENT Recorded Jun 2, 2026
From: THE UNIVERSITY OF ADELAIDE
To: ADELAIDE UNIVERSITY
Reel/Frame 075843/0344 →
Priority Claims (1)
AU 2016905096 · Dec 9, 2016 · national
Continuity (1)
Related Publication 20190382722A1 · Dec 19, 2019